{
    "organizations": [],
    "uuid": "522410f795943c7ed567f8d5c2f0e175b99ec4d2",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/30/globe-newswire-biodelivery-sciences-to-host-conference-call-and-webcast-reporting-first-quarter-2018-financial-results-on-thursday-may-10.html",
    "ord_in_thread": 0,
    "title": "BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2018 Financial Results on Thursday, May 10",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "RALEIGH, N.C., April 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close and will host a conference call and webcast on Thursday, May 10, 2018, at 4:30 PM Eastern Time.\nConference Call & Webcast\nThursday, May 10 @ 4:30pm Eastern Time\nDomestic: 800-289-0438 International: 323-794-2423 Passcode: 5157508 Webcast: http://public.viavid.com/index.php?id=129149 Replays available through May 24:\nDomestic: 844-512-2921 International: 412-317-6671 Conference ID: 5157508 About BioDelivery Sciences International, Inc.\nBioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA ® ) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.\nBDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina.\nFor more information, please visit or follow us:\nInternet: www.bdsi.com Facebook: ﻿ Facebook.com/BioDeliverySI ﻿Twitter: @BioDeliverySI BUNAVAIL ® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA ® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com .\nCautionary Note on Forward-Looking Statements\nThis press release, the presentation described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (\"BDSI\") related thereto contain, or may contain, among other things, certain \" \" within the meaning of the Private Securities Litigation Reform Act of 1995. Such involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the BDSI's plans, objectives, projections, expectations and intentions and other statements identified by words such as \"projects,\" \"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"believes,\" \"expects,\" \"anticipates,\" \"estimates,\" \"intends,\" \"plans,\" \"potential\" or similar expressions. These statements are based upon the current beliefs and expectations of the BDSI's management and are subject to significant risks and uncertainties, including those detailed in the BDSI's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Company’s commercialization programs for BELBUCA and BUNAVAIL based on the products attributes described herein) may differ significantly from those set forth or implied in the . These involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the BDSI's control). BDSI undertakes no obligation to publicly update any , whether as a result of new information, future presentations or otherwise, except as required by applicable law.\nBDSI ® , BEMA ® , ONSOLIS ® , BUNAVAIL ® and BELBUCA ® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences, BUNAVAIL and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.\n© 2018 BioDelivery Sciences International, Inc. All rights reserved.\nContact\nAl Medwar\nBioDelivery Sciences\n919-582-9050\namedwar@bdsi.com\nMonique Kosse\nManaging Director\nLifeSci Advisors\n212-915-3820\nmonique@lifesciadvisors.com\nSource:BioDelivery Sciences International, Inc.",
    "published": "2018-04-30T15:00:00.000+03:00",
    "crawled": "2018-04-30T17:58:07.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "raleigh",
        "april",
        "globe",
        "newswire",
        "biodelivery",
        "science",
        "international",
        "nasdaq",
        "bdsi",
        "specialty",
        "pharmaceutical",
        "company",
        "focus",
        "pain",
        "management",
        "addiction",
        "medicine",
        "today",
        "announced",
        "report",
        "financial",
        "result",
        "first",
        "quarter",
        "ended",
        "march",
        "market",
        "close",
        "host",
        "conference",
        "call",
        "webcast",
        "thursday",
        "may",
        "pm",
        "eastern",
        "time",
        "conference",
        "call",
        "webcast",
        "thursday",
        "may",
        "eastern",
        "time",
        "domestic",
        "international",
        "passcode",
        "webcast",
        "http",
        "replay",
        "available",
        "may",
        "domestic",
        "international",
        "conference",
        "id",
        "biodelivery",
        "science",
        "international",
        "biodelivery",
        "science",
        "international",
        "nasdaq",
        "bdsi",
        "specialty",
        "pharmaceutical",
        "company",
        "focus",
        "area",
        "pain",
        "management",
        "addiction",
        "medicine",
        "bdsi",
        "utilizing",
        "novel",
        "proprietary",
        "bioerodible",
        "mucoadhesive",
        "bema",
        "technology",
        "drug",
        "delivery",
        "technology",
        "develop",
        "commercialize",
        "either",
        "partnership",
        "third",
        "party",
        "new",
        "application",
        "proven",
        "therapy",
        "aimed",
        "addressing",
        "important",
        "unmet",
        "medical",
        "need",
        "bdsi",
        "marketed",
        "product",
        "development",
        "address",
        "serious",
        "debilitating",
        "condition",
        "chronic",
        "pain",
        "breakthrough",
        "cancer",
        "pain",
        "opioid",
        "dependence",
        "bdsi",
        "headquarters",
        "raleigh",
        "north",
        "carolina",
        "information",
        "please",
        "visit",
        "follow",
        "u",
        "internet",
        "facebook",
        "biodeliverysi",
        "bunavail",
        "buprenorphine",
        "naloxone",
        "buccal",
        "film",
        "ciii",
        "belbuca",
        "buprenorphine",
        "buccal",
        "film",
        "ciii",
        "marketed",
        "biodelivery",
        "science",
        "full",
        "prescribing",
        "information",
        "important",
        "safety",
        "information",
        "bdsi",
        "product",
        "please",
        "visit",
        "company",
        "promptly",
        "post",
        "press",
        "release",
        "sec",
        "filing",
        "important",
        "information",
        "contact",
        "company",
        "full",
        "prescribing",
        "safety",
        "information",
        "belbuca",
        "please",
        "visit",
        "full",
        "prescribing",
        "safety",
        "information",
        "bunavail",
        "please",
        "visit",
        "cautionary",
        "note",
        "statement",
        "press",
        "release",
        "presentation",
        "described",
        "herein",
        "statement",
        "employee",
        "representative",
        "partner",
        "biodelivery",
        "science",
        "international",
        "bdsi",
        "related",
        "thereto",
        "contain",
        "may",
        "contain",
        "among",
        "thing",
        "certain",
        "within",
        "meaning",
        "private",
        "security",
        "litigation",
        "reform",
        "act",
        "involve",
        "significant",
        "risk",
        "uncertainty",
        "statement",
        "may",
        "include",
        "without",
        "limitation",
        "statement",
        "respect",
        "bdsi",
        "plan",
        "objective",
        "projection",
        "expectation",
        "intention",
        "statement",
        "identified",
        "word",
        "project",
        "may",
        "could",
        "would",
        "belief",
        "expects",
        "anticipates",
        "estimate",
        "intends",
        "plan",
        "potential",
        "similar",
        "expression",
        "statement",
        "based",
        "upon",
        "current",
        "belief",
        "expectation",
        "bdsi",
        "management",
        "subject",
        "significant",
        "risk",
        "uncertainty",
        "including",
        "detailed",
        "bdsi",
        "filing",
        "security",
        "exchange",
        "commission",
        "actual",
        "result",
        "including",
        "without",
        "limitation",
        "result",
        "company",
        "commercialization",
        "program",
        "belbuca",
        "bunavail",
        "based",
        "product",
        "attribute",
        "described",
        "herein",
        "may",
        "differ",
        "significantly",
        "set",
        "forth",
        "implied",
        "involve",
        "certain",
        "risk",
        "uncertainty",
        "subject",
        "change",
        "based",
        "various",
        "factor",
        "many",
        "beyond",
        "bdsi",
        "control",
        "bdsi",
        "undertakes",
        "obligation",
        "publicly",
        "update",
        "whether",
        "result",
        "new",
        "information",
        "future",
        "presentation",
        "otherwise",
        "except",
        "required",
        "applicable",
        "law",
        "bdsi",
        "bema",
        "onsolis",
        "bunavail",
        "belbuca",
        "registered",
        "trademark",
        "biodelivery",
        "science",
        "international",
        "biodelivery",
        "science",
        "bunavail",
        "belbuca",
        "logo",
        "trademark",
        "owned",
        "biodelivery",
        "science",
        "international",
        "trademark",
        "tradenames",
        "owned",
        "respective",
        "owner",
        "biodelivery",
        "science",
        "international",
        "right",
        "reserved",
        "contact",
        "al",
        "medwar",
        "biodelivery",
        "science",
        "amedwar",
        "monique",
        "kosse",
        "managing",
        "director",
        "lifesci",
        "advisor",
        "monique",
        "source",
        "biodelivery",
        "science",
        "international",
        "inc"
    ]
}